Implantation of tumor cells modified by in vitro cytokine gene transfer has been shown by many investigators to result in potent in vivo antitumor activities in mice. Here we describe an approach to tumor immunotherapy utilizing direct transfection of cytokine genes into tumorbearing animals by particle-mediated gene transfer. In vivo transfection of the human interleukin 6 gene into the tumor site reduced methylcholanthrene-induced fibrosarcoma growth, and a combination of murine tumor necrosis factor a and interferon y genes inhibited growth of a renal carcinoma tumor model (Renca). In addition, treatment with murine interleukin 2 and interferon -y genes prolonged the survival of Renca tumor-bearing mice and resulted in tumor eradication in 25% of the test animals. Transgene expression was demonstrated in treated tissues by ELISA and immunohistochemical analysis. Significant serum levels of interleukin 6 and interferon y were detected, demonstrating effective secretion of transgenic proteins from treated skin into the bloodstream. This in vivo cytokine gene therapy approach provides a system for evaluating the antitumor properties ofvarious cytokines in different tumor models and has potential utility for human cancer gene therapy.
In situ secretion of certain cytokines by genetically modified tumor or immune system cells can induce inflammatory and/or immune responses which inhibit the growth of certain transplantable tumors. Transgenic cytokines including interleukin 2 (IL-2), IL-4, IL-6, tumor necrosis factor a (TNFa), interferon y (IFNy), and granulocyte/macrophage-colonystimulating factor have been effective in mediating either T-cell-dependent or inflammatory responses leading to tumor regression or rejection (1) (2) (3) (4) (5) (6) . Mice treated with cytokinegene-modified tumor cells often rejected subsequent challenges with unmodified tumor cells (4) (5) (6) . Several clinical trials have been initiated involving use of cytokine-genemodified autologous tumor cells (7, 8) or tumor-infiltrating lymphocytes (9, 10) for treatment of patients with advanced cancers.
Here we describe an in vivo cancer gene therapy approach in which cytokine genes are introduced into tumor-bearing animals by Accell (Agracetus) particle-mediated gene transfer (11) (12) (13) . This technology utilizes an adjustable electric discharge to generate a shock wave which accelerates DNAcoated gold particles into target cells or tissues, resulting in gene transfer. When compared with other gene delivery methods such as lipofection, calcium phosphate precipitation, or electroporation, the particle-mediated, or "gene gun," technique can achieve up to 100-fold higher transgene expression levels ex vivo or in vitro (11, 12) . This method has previously allowed highly efficient gene transfer to skin and liver tissues of live animals (13) . In this study, we have developed an in vivo gene therapy system by delivering cytokine genes directly into tumor-bearing animals. This in vivo and in situ gene transfer protocol is designed to bypass the ex vivo gene transfer approach commonly employed in previous cancer gene therapy studies.
With this strategy, we investigated several cytokines previously reported to have antitumor effects in defined animal models, including IL-2, IL-6, TNFa and IFN-y. Among a wide array of functions, IL-6 probably serves most importantly as a mediator of inflammation (14) . Antitumor activity against several murine tumor cell lines has been described (15) . Also, IL-6 gene-transfected tumor cells have been shown to have slower growth or reduced tumorigenicity (16, 17) . IFN-y plays a key role in the host response to virus or antigen stimulation and enhances monocyte and natural killer cell function (18) . It can exert direct antitumor activity and modulate immune responses by mediating delayed-type hypersensitivity, increasing expression of major histocompatibility complex-encoded antigens on tumor cells, and enhancing tumor cell susceptibility to lysis (18, 19) . In addition, IFN-y gene-transfected tumor cells have been shown to exhibit reduced tumorigenicity (20, 21) . The antitumor activities of TNFa have also been well documented. Produced by tumor-infiltrating lymphocytes and activated macrophages, it activates cytotoxic T cells and natural killer cells (4) . TNFa gene-modified tumor cells have also been demonstrated to have reduced tumorigenicity (22, 23) . Although it has potent antitumor activity, systemic administration of TNFa causes severe toxicity (24) . As a result, TNFa gene-transfected tumor-infiltrating lymphocytes or tumor cells have been injected to deliver a high local concentration of the cytokine for induction of immune responses (24) . IL-2 is known to exert antitumor activity through specific cytotoxic T lymphocytes (25) . IL-2 gene-transduced tumors have been demonstrated to attract infiltrating T lymphocytes (26) and can elicit a systemic immune response (27) . It is believed that CD8+ cells are the major IL-2-activated effector cells (25) , although recent studies have shown that natural killer cells also play a critical role in rejecting IL-2-producing tumors (28) .
We report here that efficient in vivo transgenic cytokine expression and positive antitumor effects were systematically obtained from human IL-6 (hIL-6), TNFa 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. In Vivo Gene Transfer. Plasmid DNA was purified on Qiagen columns (Qiagen, Chatsworth, CA), precipitated onto gold particles (1-3 ,um) at a density of 2.5 j,g of DNA per mg of particles, and evenly distributed onto a Mylar sheet (1.8 x 1.8 cm2; 0.1 mg of particles per cm2) as described (30) . For cotransfection experiments, two separate cytokine gene plasmid preparations were mixed and coprecipitated onto the gold particles at a dosage of 1.25 ,ug of each plasmid per mg of gold particles. Mice were placed on the Accell device (Agracetus) with the target tissues in the path of the particles. Particles were then accelerated by a 20-kV electric discharge, resulting in delivery of the DNA-laden particles to the target tissue.
Cytokine Tumor Gene Therapy Protocol. Established murine tumor cell lines were inoculated subcutaneously into the appropriate mouse host strain on the indicated days prior to the onset of treatment. After the mice were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (20 mg/kg), the surgically exposed tumor site and/or the epidermis overlaying the transplanted tumors was treated in situ with test cytokine genes or control DNA. Each treatment with DNA-coated gold particles delivered 0.8 ,ug of plasmid DNA per site. In experiments where the tumor was directly exposed to the accelerated particles, a 2-cm incision was made near the tumor site, the subcutaneous tissue was exposed, and test or control plasmid DNA was delivered into the dermis layer at the site of tumor cell injection. The incision was closed with stainless steel clips, and the epidermal tissue overlaying the injected tumor cells was bombarded with the DNA-coated particles. Four to five subsequent epidermal transfections were performed on alternate days in all experiments. In experiments testing the effects of cytokine gene transfer to the epidermis directly over the subcutaneous tumor, particle-mediated gene delivery was performed four or five times at 1-to 2-day intervals as indicated for specific experiments. Antitumor effects were measured 2 weeks (Renca) or 
and embedded in paraffin. Thin (5-,m) tissue sections were deparaffinized and incubated for 30 min with polyclonal rabbit anti-recombinant hIL-6 or anti-recombinant hTNFa antibodies (Genzyme). To eliminate crossreactivity with mIL-6 or mTNFa, primary antibodies were first incubated overnight in supernatant medium from lipopolysaccharidestimulated mouse bone marrow cells. Sections were washed with 0.05 M Tris, pH 7.5/10% ethanol/0.25% Tween 20 and incubated with biotinylated goat anti-rabbit IgG for 30 min. After washing, ABC-peroxidase reagent was applied (Vector Laboratories) and avidin-biotin immunocomplexes were visualized with metal-enhanced diaminobenzidine and hydrogen peroxide (Pierce).
RESULTS AND DISCUSSION
Antitumor effects and transgene expression levels of three sets of cytokine genes were evaluated in the present gene therapy study, utilizing a particle-mediated technique for in vivo gene transfer. These cytokine genes, including IL-6, IFNy, TNFa, and IL-2, were initially selected for their reported antitumor effects in specific mouse tumor models and were later found in preliminary screening (data not shown) to confer an apparent antitumor activity. Systematic experiments using these cytokines were then executed, with the results described below.
IL-6. Data from several independent experiments showed that subcutaneous methylcholanthrene-induced fibrosarcoma (SP1) tumors exhibited a reduced growth rate when tumorbearing mice were treated with hIL-6 DNA, compared with cohorts that received a control DNA vector (Fig. 1A) . In initial experiments, both epidermal and dermal tissues surrounding the inoculated tumor were treated. Later experiments showed that epidermal transfections alone resulted in a similar reduction in tumor growth (Fig. 1B) , and that the majority of hIL-6 expression resulted from epidermal gene delivery (Fig. 1D) . At the discharge voltages used in this study, DNA-coated gold particles effectively transfect epidermal tissues; however, particle penetration to the subcutaneous tumor cells is limited. Thus, these findings suggest that localized expression of hIL-6 by nearby normal tissues plays a key role in the antitumor response. When the epidermal DNA treatments were initiated 5 days after tumor cell inoculation, a similar level of tumor growth reduction was observed (50%), suggesting that in vivo transfection with the hIL-6 gene is effective against established tumors.
Histology of the bombarded tissues revealed that the gold particles penetrated three to five cell layers and were primarily located in the skin tissue peripheral to the tumor mass. Immunohistochemistry with an antibody specific for hIL-6 distinctly showed transgenic hIL-6 expression by squamous cells in the epidermal layer (Fig. 2 Upper) . To measure the level of transgenic IL-6 production, serum samples, tumors and nearby tissues were collected from in vivo transfected mice following euthanization. Two days after transfection, IL-6 levels reached 40 pg/ml in serum (Fig. 1 C) and remained at detectable levels (1-5 pg/ml) for up to 7 days as measured by ELISA. The tumor and associated skin tissue extracts contained much higher levels of IL-6, ranging from 200 to 600 pg/ml (Fig. 1D) . Thus, high levels of hIL-6 were expressed locally and in serum, compared with the mean physiological concentration of IL-6 in human serum, 1.6 pg/ml (31) . The high-level, localized transgene expression apparently creates a cytokine protein gradient from which the transgenic hIL-6 can dissipate into the blood stream via diffusion. Although in the present experiments the mechanism by which IL-6 suppresses tumor growth is not quite clear, both cytotoxic T-cell and inflammatory responses have been previously demonstrated (32). IFNy plus TNFa. Cotransfection of IFN-y and TNFa genes in vivo by particle bombardment resulted in a drastic reduction of subcutaneous Renca tumor growth (Fig. 3 A and B) . Three 00.
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FIG. 2.
Immunoperoxidase staining of transgenic hIL-6 (Upper) and hTNFa (Lower) proteins expressed in bombarded skin tissues 24 hr after in vivo transfection with the corresponding cDNAs. experiments, each with 11 or 12 animals per treatment set, showed highly reproducible effects. Compared with controls, average tumor weights excised from mIFNy/hTNFa-treated animals were reduced by 42%, 48%, and 69% (one-tailed aggregate P value < 0.002). As in the IL-6 experiments, we found that epidermal gene deliveries alone resulted in a reduction of tumor growth (Fig. 2B) . Results of three independent mIFNy/mTNFa experiments showed average tumor weight reductions of 58%, 69%, and 87% (one-tailed aggregate P value -< 0.001). Also, mIFNy/mTNFa gene treatments initiated 5 days rather than 1 day after tumor cell inoculation also resulted in a 35% reduction in average tumor weight (one-tailed P value = 0.06, n = 10). Tissue and serum collected for cytokine measurements 24 hr after transfection contained high levels of transgenic IFNy and TNFa (Fig. 3 C and D) . Circulating IFNy levels in the test animals were 186 pg/ml compared with < 1 pg/ml in the controls, which is significantly higher than the normal physiological concentration of IFNy in human serum, <10 pg/ml (33) .
Immunohistochemical analysis revealed that transgenic hTNFa was produced by the epidermal squamous cells (Fig. 2 Lower). Since the three cytokines studied here showed high expression levels and similar immunohistochemical staining patterns, these studies confirm that particle-mediated gene transfer is a highly efficient technology for expression of transgenic cytokines in vivo.
IL-2 plus IFN'y. The effects of mIL-2/IFNy cytokine gene therapy on the survival of tumor-bearing mice were examined. Renca tumor-bearing mice treated with a combination of murine IL-2 and IFNy genes had significantly increased survival compared with mice that received a control vector (Fig.  4) 
